Peptidream Announces The Development Of A New Broad Strain Anti-Influenza Macrocyclic Peptide Therapeutic
4/8/2014 9:34:29 AM
TOKYO--(BUSINESS WIRE)--PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”)( TOKYO:4587) announced today, in collaboration with The Tokyo Metropolitan Institute of Medical Science (“Tokyo Metropolitan Institute”) the discovery and development of a novel macrocyclic peptide inhibitor for the treatment of multiple influenza strains.
Help employers find you! Check out all the jobs and post your resume.
comments powered by